Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics (Nasdaq: EWTX), a biopharmaceutical company focused on muscle diseases, has granted inducement stock options to 2 new non-executive employees. The options allow the purchase of 16,500 shares at an exercise price of $14.35 per share, matching the closing price on the grant date of August 29, 2025.
The options, granted under the company's 2024 Inducement Equity Incentive Plan, will vest over four years, with 25% vesting after one year and the remaining vesting monthly at a rate of 1/48th, contingent on continued employment. These grants comply with Nasdaq Listing Rule 5635(c)(4) as employment inducements.
Edgewise Therapeutics (Nasdaq: EWTX), societ脿 biofarmaceutica specializzata nelle malattie muscolari, ha assegnato opzioni azionarie d'induzione a 2 nuovi dipendenti non esecutivi. Le opzioni consentono l'acquisto di 16.500 azioni a un prezzo di esercizio di $14,35 per azione, pari al prezzo di chiusura del giorno di assegnazione del 29 agosto 2025.
Le opzioni, concesse ai sensi del piano di incentivazione azionaria d'induzione 2024 della societ脿, matureranno in quattro anni: il 25% dopo un anno e il restante maturer脿 mensilmente a un tasso di 1/48, subordinato alla continuazione del rapporto di lavoro. Queste assegnazioni sono conformi alla regola di quotazione Nasdaq 5635(c)(4) come incentivi per l'assunzione.
Edgewise Therapeutics (Nasdaq: EWTX), una biotecnol贸gica centrada en enfermedades musculares, ha otorgado opciones sobre acciones como incentivo a 2 nuevos empleados no ejecutivos. Las opciones permiten la compra de 16.500 acciones a un precio de ejercicio de $14,35 por acci贸n, equivalente al precio de cierre en la fecha de concesi贸n del 29 de agosto de 2025.
Las opciones, concedidas bajo el Plan de Incentivos de Capital por Inducci贸n 2024 de la compa帽铆a, se consolidar谩n a lo largo de cuatro a帽os: el 25% tras un a帽o y el resto se consolidar谩 mensualmente a raz贸n de 1/48, condicionado a la continuidad en el empleo. Estas concesiones cumplen la Norma de Cotizaci贸n Nasdaq 5635(c)(4) como incentivos por contrataci贸n.
Edgewise Therapeutics (Nasdaq: EWTX), 攴检湣 歆堩櫂鞐� 欤茧牓頃橂姅 氚旍澊鞓れ牅鞎届偓鞚� 鞚� 須岇偓電� 2氇呾潣 鞁犼窚 牍勳瀯鞗� 歆侅洂鞐愱矊 鞙犾澑 欤检嫕毵れ垬靹犿儩甓岇潉 攵�鞐枅鞀惦媹雼�. 頃措嫻 鞓奠厴鞚� 16,500欤�毳� 欤茧嫻 $14.35鞚� 頄夓偓臧�搿� 毵れ垬頃� 靾� 鞛堧姅 甓岆Μ搿�, 攵�鞐澕鞚� 2025雲� 8鞗� 29鞚� 膦呹皜鞕� 霃欖澕頃╇媹雼�.
鞚� 鞓奠厴霌れ潃 須岇偓鞚� 2024雲� 鞙犾澑順� 欤检嫕氤挫儊瓿勴殟鞐� 霐半澕 攵�鞐悩鞐堨溂氅�, 4雲勳棎 瓯胳硱 氩犾姢韺呺惄雼堧嫟. 1雲� 頉� 25%臧� 氩犾姢韸�霅橂┌, 雮橂ǜ歆�電� 瓿犾毄 歆�靻嶌潉 臁瓣贝鞙茧 毵れ洈 1/48鞌� 氩犾姢韺呺惄雼堧嫟. 鞚� 攵�鞐姅 瓿犾毄 鞙犾澑鞚� 鞙勴暅 Nasdaq 靸侅灔攴滌爼 5635(c)(4)毳� 欷�靾橅暕雼堧嫟.
Edgewise Therapeutics (Nasdaq: EWTX), une soci茅t茅 biopharmaceutique ax茅e sur les maladies musculaires, a accord茅 des options d'incitation 脿 2 nouveaux employ茅s non ex茅cutifs. Les options permettent l'achat de 16 500 actions au prix d'exercice de 14,35 $ par action, correspondant au cours de cl么ture 脿 la date d'attribution du 29 ao没t 2025.
Ces options, accord茅es dans le cadre du Plan d'incitation en actions 2024 de la soci茅t茅, seront acquises sur une p茅riode de quatre ans : 25 % apr猫s un an et le solde s'acquerra mensuellement 脿 raison de 1/48, sous r茅serve de la poursuite de l'emploi. Ces attributions sont conformes 脿 la r猫gle de cotation Nasdaq 5635(c)(4) en tant qu'incitations 脿 l'embauche.
Edgewise Therapeutics (Nasdaq: EWTX), ein biopharmazeutisches Unternehmen mit Schwerpunkt auf Muskelerkrankungen, hat Einf眉hrungsaktienoptionen an 2 neue nicht gesch盲ftsf眉hrende Mitarbeiter gew盲hrt. Die Optionen erm枚glichen den Kauf von 16.500 Aktien zu einem Aus眉bungspreis von $14,35 je Aktie, entsprechend dem Schlusskurs am Zuteilungsdatum 29. August 2025.
Die unter dem Inducement Equity Incentive Plan 2024 gew盲hrten Optionen werden 眉ber vier Jahre vesten: 25 % nach einem Jahr, der Rest vestet anschlie脽end monatlich zu je 1/48, abh盲ngig vom Fortbestehen des Besch盲ftigungsverh盲ltnisses. Diese Zuteilungen entsprechen der Nasdaq-Listing-Regel 5635(c)(4) als Einstellungsvorteile.
- None.
- None.
Each inducement stock option has an exercise price of
Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4).聽
About Edgewise Therapeutics聽
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to:聽聽or follow us on聽,听聽,听听补苍诲听.
View original content to download multimedia:
SOURCE Edgewise Therapeutics
FAQ
What stock options did Edgewise Therapeutics (EWTX) grant to new employees in August 2025?
What is the vesting schedule for EWTX's August 2025 inducement stock options?
What is the purpose of Edgewise Therapeutics' 2024 Inducement Equity Incentive Plan?
How many new employees received stock options from EWTX in August 2025?
